Posted by Michael Wonder on 20 Jun 2023
US FDA approves first anti-inflammatory drug for cardiovascular disease
20 June 2023 - Lodoco can reduce the risk of cardiac events in patients with established cardiovascular diseases by 31% on top of standard of care, will be available for prescription in the second half of 2023.
Agepha Pharma today announced that, following a priority review, the US FDA has approved Lodoco as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction, stroke, coronary revascularisation, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
